PharmaDiversityJobBoard-Diversity Job Board connecting diversity & minority job seekers with Pharmaceutical jobs. GE Healthcare Jobs (GE)
  Home  |  Login  |  Job Seeker Register  |  Employer Register    You're not logged in!
Translate:

AMGEN Jobs

 
Click links to read Current News for this Featured Employer    Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial | Amgen?s Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38 | Amgen Announces Webcast of 2010 Second Quarter Financial Results | Amgen Appoints Ronald D. Sugar to the Company's Board of Directors | Amgen Scholars' Summer Research Helps Lead to Science Careers | Amgen Appoints Jonathan M. Peacock Executive Vice President and Chief Financial Officer | Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients for Better Outcomes | Amgen to Present at the Goldman Sachs Global Healthcare Conference | Amgen to Present at the Jeffries Global Life Sciences Conference | Denosumab Demonstrated Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Prostate Cancer | New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care | Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union | Amgen Highlights Key Clinical Data to Be Presented at American Society of Clinical Oncology Annual Meeting | Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients | Amgen Announces Voting Results of Annual Meeting of Stockholders | Amgen's Breakaway From Cancer(R) to Honor Cancer Survivors at Amgen Tour of California | Amgen Scientists Visit Biotechnology Classrooms Across the Country in Support of National Lab Day | Amgen to Present at the Deutsche Bank 35th Annual Healthcare Conference | Amgen Appoints Robert A. Bradway President and Chief Operating Officer | Amgen?s First Quarter 2010 Adjusted Earnings Per Share Increased 20 Percent to $1.30 | Amgen Announces Webcast of 2010 First Quarter Financial Results | Amgen Highlights Biomarker and Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting | Amgen to Present at the Cowen and Company 30th Annual Healthcare Conference | Cardiac Science Sets Date for Fourth Quarter, Year-End Results Release and Conference Call | FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date | Amgen and Centocor Ortho Biotech Products Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA | Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases | Dempsey Challenge Participant Registration Officially Open | Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share Increased 8 Percent to $4.91 | Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium | Amgen to Present at the 28th Annual JP Morgan Healthcare Conference | Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines | Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union | Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care | Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum | Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP | Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program | Amgen Highlights Data to be Presented at ASH | Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards | Amgen to Present at Lazard Capital Healthcare Conference | Amgen to Present at 18th Annual Credit Suisse Healthcare Conference | Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer Phase 3 Results Reinforce Importance of KRAS Status | Call for Applications: The Amgen Award for Science Teaching Excellence 34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates | Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA) | Amgen Announces Webcast of 2009 Third Quarter Financial Results | 200 Cyclists to Ride in Arthritis Foundation's Amgen California Coast Classic Bike Tour to Raise $1 Million Cyclists from across the country will bike down the California coast to raise funds and help those affected by arthritis | Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer | Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients | Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer | Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases | Amgen to Present at the UBS Global Life Sciences Conference | Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented | Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference | Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting | Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope | Amgen to Present at the Thomas Weisel Healthcare Conference | Amgen to Present at the Baird Healthcare Conference | Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes No Statistically Significant Difference in Cardiovascular and Renal Composite Endpoints Between Aranesp and Placebo | Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer Second Prospective Phase 3 Vectibix Combination Chemotherapy Trial to Show Progression-Free Survival Advantage in KRAS Wild-Type Population | Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting | Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs Committee to Review Denosumab in Women with Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation Therapy for Either Prostate or Breast Cancer | Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer Pivotal Study Meets Primary Endpoint of Progression-Free Survival in Wild-Type KRAS Population Phase 3 Results Reinforce Importance of KRAS Testing | Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers | Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary EndpointDenosumab Delayed Time to Skeletal Related Events | Economy Is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease - National Census Data Shows Osteoporosis Rates to Increase by an Estimated 30(1) Percent Among D.C. Residents by 2020 -- Special Council of Health and Women's Groups Formed to Encourage Women to Make Bone Health a Priority Before They Break a Bone - | Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) Amgen to Retain Full Rights for Denosumab in the United States and Canada and for Oncology Indications in EuropeGlaxoSmithKline Will Commercialize Denosumab for PMO and Oncology in Emerging Markets | Amgen Announces Webcast of 2009 Second Quarter Financial Results | Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium | Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab) Class Labeling Recognizes KRAS as a Predictive Biomarker for anti-EGFr Antibody Monotherapy in Metastatic Colorectal Cancer Results from First Pivotal Trials Prospectively Evaluating KRAS Utility in Combination Therapy Expected In Third Quarter 2009 | Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors | Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August | Amgen to Present at the Goldman Sachs Global Healthcare Conference | New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP | Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452 | Amgen Highlights Data to Be Presented at ASCO | Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference | Amgen Announces Voting Results Of Annual Meeting Of Stockholders | Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08 | Amgen Announces Webcast of 2009 First Quarter Financial Results | Amgen to Present at the Citigroup Biotech Day | Amgen to Present at the Barclays Capital Global Healthcare Conference | FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab | Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | AMDL Chairman & CEO Mr. Douglas MacLellan Featured on Fox Business News Monday February 2, 2009 | Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 | Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services | Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results | Amgen to Present at the 27th Annual JP Morgan Healthcare Conference | Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer | Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients | Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union | Amgen Positioned to Deliver Attractive Growth Over Next Five Years | Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York | Call for Applications: The Amgen Award for Science Teaching Excellence | 240 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.1 Million for Arthritis Foundation |
 
  
Items 1-25/242 displayed. [1-25][26-50][51-75][76-100][101-125][126-150][151-175][176-200][201-225][226-242] next
SaveDateJob TitleCity CountryStateCompany NamePay
Sep 02 Material Coordinator
 Thousand Oaks California  AMGEN Not specified
Sep 02 Medical Writing Manager Oncology
 Thousand Oaks California  AMGEN Not specified
Aug 31 Epidemiology Mgr
 Any, United States   AMGEN Not specified
Aug 31 Dir Regulatory Writing
 Any, United States   AMGEN Not specified
Aug 31 Sr Project Mgr
 Thousand Oaks California  AMGEN Not specified
Aug 31 Sr Regional Medical Liaison
 Field Based New JerseyUnited States  AMGEN Not specified
Aug 31 Sr Biopharmaceutical Rep, Bone Health - Tulsa, OK
 Field Based Oklahoma  AMGEN Not specified
Aug 31 Associate Government Affairs
 Washington D.C. District of Columbia  AMGEN Not specified
Aug 27 Medical Communications Senior Manager Bone TA
 Thousand Oaks California  AMGEN Not specified
Aug 27 Sr Biopharmaceutical Rep, Bone Health - Beverly Hills, CA
 Los Angeles - Field Based California  AMGEN Not specified
Aug 27 Admin Coordinator
 Atlanta - Field Based Georgia  AMGEN Not specified
Aug 27 Admin Coordinator
 Atlanta - Field Based Georgia  AMGEN Not specified
Aug 26 Senior Executive Assistant
 Thousand Oaks California  AMGEN Not specified
Aug 26 Finance Mgr
 Any, United States   AMGEN Not specified
Aug 26 Sr Scientist
 Seattle Washington  AMGEN Not specified
Aug 26 Associate Scientist
 Seattle Washington  AMGEN Not specified
Aug 26 Government Affairs Sr Mgr
 Washington D.C. District of Columbia  AMGEN Not specified
Aug 25 Mfg Process Technician- AML 1 Transfer Point
 Juncos Puerto Rico  AMGEN Not specified
Aug 25 Clinical Research Medical Director - Oncology
 Thousand Oaks California  AMGEN Not specified
Aug 25 Clinical Research Medical Director - Dermatology
 Thousand Oaks California  AMGEN Not specified
Aug 25 Senior Scientist Bioinformatics Hematology Oncology
 CambridgeSeattleSouth San FranciscoThousand Oaks CaliforniaUnited States  AMGEN Not specified
Aug 25 Sr Engineer
 Field BasedJuncos Puerto Rico  AMGEN Not specified
Aug 24 Associate Scientist
 South San Francisco California  AMGEN Not specified
Aug 24 Associate Scientist
 South San Francisco California  AMGEN Not specified
Aug 24 Hospital System Mgr (Sales Representative) - Washington, D.C.
 Field Based District of Columbia  AMGEN Not specified